SNDX vs. AGIO, KROS, GERN, PTGX, MLTX, KDNY, GMTX, ZNTL, DVAX, and AUPH
Should you be buying Syndax Pharmaceuticals stock or one of its competitors? The main competitors of Syndax Pharmaceuticals include Agios Pharmaceuticals (AGIO), Keros Therapeutics (KROS), Geron (GERN), Protagonist Therapeutics (PTGX), MoonLake Immunotherapeutics (MLTX), Chinook Therapeutics (KDNY), Gemini Therapeutics (GMTX), Zentalis Pharmaceuticals (ZNTL), Dynavax Technologies (DVAX), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical preparations" industry.
Syndax Pharmaceuticals vs.
Agios Pharmaceuticals (NASDAQ:AGIO) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability, community ranking and analyst recommendations.
Agios Pharmaceuticals has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500.
Syndax Pharmaceuticals has higher revenue and earnings than Agios Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Syndax Pharmaceuticals has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -1,146.58%. Agios Pharmaceuticals' return on equity of -20.23% beat Syndax Pharmaceuticals' return on equity.
Agios Pharmaceuticals received 129 more outperform votes than Syndax Pharmaceuticals when rated by MarketBeat users. Likewise, 68.44% of users gave Agios Pharmaceuticals an outperform vote while only 64.79% of users gave Syndax Pharmaceuticals an outperform vote.
In the previous week, Agios Pharmaceuticals had 3 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 5 mentions for Agios Pharmaceuticals and 2 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 1.64 beat Agios Pharmaceuticals' score of 1.48 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media.
99.1% of Syndax Pharmaceuticals shares are owned by institutional investors. 4.2% of Agios Pharmaceuticals shares are owned by insiders. Comparatively, 4.7% of Syndax Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Agios Pharmaceuticals currently has a consensus price target of $37.00, indicating a potential upside of 46.36%. Syndax Pharmaceuticals has a consensus price target of $33.86, indicating a potential upside of 69.54%. Given Syndax Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Agios Pharmaceuticals.
Summary
Syndax Pharmaceuticals beats Agios Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SNDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Syndax Pharmaceuticals Competitors List
Related Companies and Tools
